IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression

Leukemia

Volumn 30, Issue 4, 2016, Pages 980-984

  Di Nardo, C D ^a   Jabbour, E ^a   Ravandi, F ^a   Takahashi, K ^a   Daver, N ^a   Routbort, M ^a   Patel, K P ^a   Brandt, M ^a   Pierce, S ^a   Kantarjian, H ^a   Garcia Manero, G ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 2, HUMAN; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; CHROMOSOME ABERRATION; DISEASE COURSE; FEMALE; GENE MUTATION; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; NEXT GENERATION SEQUENCING; OVERALL SURVIVAL; PREVALENCE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA AND RINGED SIDEROBLASTS; CANCER STAGING; FOLLOW UP; GENETICS; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; ISOCITRATE DEHYDROGENASE; MALE; MIDDLE AGED; MUTATION; MYELODYSPLASTIC SYNDROMES; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; YOUNG ADULT;

EID: 84939558433     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.211     Document Type: Letter

References (15)

1. Im AP, Sehgal AR, Carroll MP, Smith BD, Tefferi A, Johnson DE, et al. DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies. Leukemia 2014; 28: 1774-1783
2. DiNardo CD, Ravandi F, Agresta S, Konopleva M, Takahashi K, Kadia T, et al. Characteristics, clinical outcome and prognostic significance of IDH mutations in AML. Am J Hematol 2015; 90: 732-736
3. Pardanani A, Patnaik MM, Lasho TL, Mai M, Knudson RA, Finke C, et al. Recurrent IDH mutations in high-risk myelodysplastic syndrome or acute myeloid leukemia with isolated del(5q). Leukemia 2010; 24: 1370-1372
4. Kosmider O, Gelsi-Boyer V, Slama L, Dreyfus F, Beyne-Rauzy O, Quesnel B, et al. Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukemia 2010; 24: 1094-1096
5. Thol F, Weissinger EM, Krauter J, Wagner K, Damm F, Wichmann M, et al. IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Haematologica 2010; 95: 1668-1674
6. Rocquain J, Carbuccia N, Trouplin V, Raynaud S, Murati A, Nezri M, et al. Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias. BMC Cancer 2010; 10: 401
7. Lin CC, Hou HA, Chou WC, Kuo YY, Liu CY, Chen CY, et al. IDH mutations are closely associated with mutations of DNMT3A, ASXL1 and SRSF2 in patients with myelodysplastic syndromes and are stable during disease evolution. Am J Hematol 2014; 89: 137-144
8. Patnaik MM, Hanson CA, Hodnefield JM, Lasho TL, Finke CM, Knudson RA, et al. Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients. Leukemia 2012; 26: 101-105
9. Green A, Beer P. Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. N Engl J Med 2010; 362: 369-370
10. Molenaar RJ, Thota S, Nagata Y, Patel B, Clemente M, Hirsh C, et al. Clinical and biological implications of ancestral and non-Ancestral IDH1 and IDH2 mutations in myeloid neoplasms. Leukemia; 2015; 29: 2134-2142
11. Patel KP, Ravandi F, Ma D, Paladugu A, Barkoh BA, Medeiros LJ, et al. Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features. Am J Clin Pathol 2011; 135: 35-45
12. Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 2013; 122: 3616-3627, quiz 99
13. Meggendorfer M, Roller A, Haferlach T, Eder C, Dicker F, Grossmann V, et al. SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). Blood 2012; 120: 3080-3088
14. Haferlach T, Nagata Y, Grossmann V, Okuno Y, Bacher U, Nagae G, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 2014; 28: 241-247
15. Takahashi K, Jabbour E, Wang X, Luthra R, Bueso-Ramos C, Patel K, et al. Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML. Leukemia 2013; 27: 2081-2083